Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection

The study consists of a 4-weeks data recording period, during which the follow-up information recorded by physicians in electronic or paper medical history will be analyzed from patients who opted for a change to that study pattern (RAL and ABC / 3TC).

Primary outcomes

• Effectiveness: Proportion of patients with undetectable viral load [48 weeks]: Effectiveness in the virological control of RAL and ABC / 3TC

Secondary outcomes

• Safety-changes in renal function: changes in creatinine values [24 weeks following the change]
• Safety-changes in renal function: changes in glomerular filtration [24 weeks following the change]
• Safety: Changes in serum levels of AST, ALT, FA, GGT and BIL [24 weeks following the change]
• Safety: Changes in serum levels of AST, ALT, FA, GGT and BIL [48 weeks following the change]
• Safety: Changes in serum cholesterol [24 weeks following the change]: HDL and LDL cholesterol
• Safety: Changes in serum triglycerides [24 weeks following the change]
• Safety: Changes in serum cholesterol [48 weeks following the change]: HDL and LDL cholesterol
• Safety: Changes in serum triglycerides [48 weeks following the change]
• Safety: Adverse events. [24 weeks/48 weeks]: Frequency of adverse events
• Safety:serious adverse events [24 weeks/48 weeks]: Frequency of serious adverse events
• Safety: frequency of adverse events leading to discontinuation of treatment. [24 weeks/48 weeks]
• Safety: number of deaths [24 weeks/48 weeks]
• Safety: frequency of laboratory abnormalities. [24 weeks/48 weeks]

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Patient with chronic infection with HIV-1.
* Patients older than 18 years.
* Patients in ART in whom RAL + ABC / 3TC has been initiated in at least 48 Weeks prior to the start of the study.
* To have used the RAL + ABC / 3TC as a switching or change strategy
* HIV virological control (CV ≤ 50 copies / ml) for at least 24 weeks prior to initiation of study regimen

Exclusion Criteria:

* NAIVE patients who have started treatment with this regimen
* Absence of digital or physical records of visits made for consultation
* Patients who underwent treatment change within 48 weeks prior to study initiation